Navigation Links
Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

Data from the mechanistic study being presented at the EASD meeting demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the presentation from the EASD meeting, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeu
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
2. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
4. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
5. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
6. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
7. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
8. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
9. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
11. Lexicon to Provide First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... A lot of discussion in the medical community revolves around ... or conditions. As medical science advances, doctors and surgeons often ... they consider to be more cutting edge. Yet, when it ... of treatment that stands out as the best solution in ...
(Date:1/23/2015)... WYNNEWOOD, Pa. , Jan. 23, 2015  MedScope ( ... has been nominated for a 2015 Connected World ... Personal Emergency Response System (mPERS), that can be used ... M2M technology partner.  In nominating MedScope, ...
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader ... and partnership with RCA Medical, a subsidiary of Ascendis ... . Each year, hundreds of millions of ... infections as organisms are transmitted from patient to patient ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
...   OncoSec Medical Incorporated (OTCBB:ONCS), which is ... therapies to treat solid tumor cancers, today announced ... company,s Phase II Merkel cell carcinoma clinical trial, ... The Journal Newspaper.    (Logo: ...
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ("AcelRx"), ... commercialization of innovative therapies for the treatment of acute ... in a Phase 3 study for ARX-01, the Sufentanil ... This first ARX-01 Phase 3 study is a randomized, ...
Cached Medicine Technology:OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 2OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 3OncoSec's OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 2AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 3AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 4AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain 5
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... the risks and benefits of short-term use of hormone therapy ... increase their quality of life, but they may also shorten ... ,Deciding whether or not to use hormone therapy can be ... for menopausal symptoms, but are the risks worth the benefits? ...
... have to be born if it starts to have complications in ... new study done in this area may shed some light on ... small delay could reduce the risk of a disability for the ... of delaying a delivery to an immediate delivery for a premature ...
... one-third of patients don’t get a prescription for a ... failure, a condition in which the heart has trouble ... they say that those who don’t receive an angiotensin-converting ... one year than those who do get the drug. ...
... popping vitamin pills won’t help ward off heart disease ... // the oxidative stress thought to play a part ... the topic, researchers could not find enough evidence in ... or prevent heart attacks or strokes. Instead, researchers suggest ...
... be to blame for you feeling depressed. Researchers surveyed ... Americans spend about three days a months feeling sad, ... did not smoke reported fewer days of depression. Researchers ... blue or depressed and engaging in behaviors risky to ...
... Naltrexone, also known as ReVia, is an approved drug for ... with the drug is it is taken orally, which can ... the body. A new study looks at an injection of ... ,For the study 315 alcoholics participated and they were ...
Cached Medicine News:
Weight adjuster flexible back, comfortably places more weight on hips, less weight on shoulders....
The Skirts and Vests are made with .50mm Pb in the front and .25mm Pb in the back. When worn, the overlap areas in the front of both the skirt and vest provide 1.0mm Pb protection. The velcro fastene...
Designed to fit the body and priced to fit the budget! The Economy Tie apron has a belt that wraps around the body and ties in the front. Don't let the price fool you.... this apron provides the same...
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Medicine Products: